| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 12 | 2020 | 401 | 1.240 |
Why?
|
| Phosphatidylinositol 3-Kinases | 5 | 2016 | 44 | 0.820 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 5 | 2012 | 23 | 0.780 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2020 | 67 | 0.750 |
Why?
|
| Epithelial Cells | 7 | 2018 | 70 | 0.690 |
Why?
|
| Cell Proliferation | 12 | 2020 | 168 | 0.610 |
Why?
|
| Mutation | 8 | 2021 | 328 | 0.560 |
Why?
|
| Estrogen Receptor alpha | 3 | 2012 | 15 | 0.540 |
Why?
|
| Cytostatic Agents | 1 | 2016 | 2 | 0.490 |
Why?
|
| Lithium | 6 | 2005 | 19 | 0.470 |
Why?
|
| Aspirin | 1 | 2016 | 48 | 0.470 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2020 | 113 | 0.470 |
Why?
|
| Breast | 4 | 2011 | 23 | 0.440 |
Why?
|
| Cell Line, Tumor | 14 | 2020 | 246 | 0.410 |
Why?
|
| Tamoxifen | 3 | 2014 | 30 | 0.400 |
Why?
|
| Magnesium | 4 | 2004 | 35 | 0.310 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2018 | 31 | 0.310 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2018 | 19 | 0.290 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2008 | 10 | 0.290 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 198 | 0.280 |
Why?
|
| MAP Kinase Signaling System | 3 | 2019 | 36 | 0.270 |
Why?
|
| Humans | 31 | 2021 | 23355 | 0.250 |
Why?
|
| Phosphorylation | 5 | 2016 | 132 | 0.240 |
Why?
|
| Neoplasms | 1 | 2008 | 221 | 0.240 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2017 | 33 | 0.230 |
Why?
|
| Gene Expression Regulation | 1 | 2006 | 236 | 0.220 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 5 | 2016 | 10 | 0.210 |
Why?
|
| Membrane Proteins | 2 | 2020 | 151 | 0.210 |
Why?
|
| Trastuzumab | 2 | 2020 | 26 | 0.210 |
Why?
|
| Receptor, ErbB-2 | 2 | 2020 | 52 | 0.200 |
Why?
|
| Estrogens | 3 | 2014 | 26 | 0.190 |
Why?
|
| Female | 16 | 2020 | 13149 | 0.190 |
Why?
|
| Bipolar Disorder | 5 | 2004 | 99 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2019 | 58 | 0.170 |
Why?
|
| Neoadjuvant Therapy | 1 | 2020 | 62 | 0.170 |
Why?
|
| STAT6 Transcription Factor | 1 | 2020 | 10 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 15 | 0.160 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2020 | 16 | 0.160 |
Why?
|
| Mice | 6 | 2020 | 1241 | 0.160 |
Why?
|
| Animals | 8 | 2020 | 3301 | 0.160 |
Why?
|
| Receptors, Estrogen | 2 | 2017 | 62 | 0.150 |
Why?
|
| Class Ia Phosphatidylinositol 3-Kinase | 1 | 2019 | 3 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 240 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 56 | 0.150 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 236 | 0.150 |
Why?
|
| Ion Channels | 1 | 2020 | 205 | 0.140 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 2 | 2016 | 10 | 0.140 |
Why?
|
| Macrophages | 1 | 2018 | 98 | 0.140 |
Why?
|
| Signal Transduction | 5 | 2019 | 404 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 88 | 0.130 |
Why?
|
| Lipid Metabolism | 1 | 2017 | 32 | 0.130 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 542 | 0.120 |
Why?
|
| MCF-7 Cells | 1 | 2016 | 15 | 0.120 |
Why?
|
| Gene Targeting | 3 | 2019 | 9 | 0.120 |
Why?
|
| ras Proteins | 2 | 2013 | 12 | 0.120 |
Why?
|
| Erythrocytes | 3 | 2004 | 17 | 0.120 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 230 | 0.120 |
Why?
|
| Hydrolases | 1 | 2014 | 2 | 0.110 |
Why?
|
| DNA Repair Enzymes | 1 | 2014 | 8 | 0.110 |
Why?
|
| Ion Transport | 2 | 2003 | 28 | 0.100 |
Why?
|
| Prognosis | 3 | 2014 | 740 | 0.100 |
Why?
|
| Middle Aged | 7 | 2020 | 8072 | 0.100 |
Why?
|
| Precancerous Conditions | 2 | 2018 | 25 | 0.100 |
Why?
|
| Receptors, Androgen | 1 | 2012 | 6 | 0.090 |
Why?
|
| Magnetic Resonance Spectroscopy | 4 | 2005 | 32 | 0.090 |
Why?
|
| Haploinsufficiency | 1 | 2011 | 2 | 0.090 |
Why?
|
| Genomic Instability | 1 | 2011 | 8 | 0.090 |
Why?
|
| Genes, BRCA1 | 1 | 2011 | 12 | 0.090 |
Why?
|
| Cell Cycle | 2 | 2008 | 33 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2009 | 86 | 0.090 |
Why?
|
| Lithium Compounds | 1 | 2011 | 3 | 0.090 |
Why?
|
| Up-Regulation | 4 | 2017 | 145 | 0.090 |
Why?
|
| ErbB Receptors | 1 | 2011 | 54 | 0.080 |
Why?
|
| RNA, Small Interfering | 3 | 2020 | 77 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2020 | 2989 | 0.080 |
Why?
|
| Gene Knockdown Techniques | 2 | 2020 | 41 | 0.080 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2019 | 13 | 0.080 |
Why?
|
| Carcinoma, Small Cell | 1 | 2009 | 53 | 0.080 |
Why?
|
| Oncogenes | 1 | 2009 | 11 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 2 | 2007 | 82 | 0.080 |
Why?
|
| Transcription, Genetic | 1 | 2009 | 98 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 112 | 0.070 |
Why?
|
| Cell Cycle Proteins | 1 | 2008 | 16 | 0.070 |
Why?
|
| Cell Nucleus | 1 | 2008 | 69 | 0.070 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 91 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2009 | 135 | 0.070 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2007 | 3 | 0.070 |
Why?
|
| Cell Membrane | 2 | 2005 | 88 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 116 | 0.070 |
Why?
|
| DNA Mutational Analysis | 1 | 2007 | 50 | 0.070 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2007 | 5 | 0.070 |
Why?
|
| Genes, ras | 1 | 2007 | 13 | 0.070 |
Why?
|
| Multiple Myeloma | 1 | 2007 | 18 | 0.070 |
Why?
|
| Repressor Proteins | 1 | 2007 | 33 | 0.070 |
Why?
|
| Mice, Knockout | 1 | 2008 | 283 | 0.070 |
Why?
|
| Heterografts | 2 | 2020 | 16 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 115 | 0.060 |
Why?
|
| DNA Methylation | 1 | 2007 | 129 | 0.060 |
Why?
|
| Intracellular Fluid | 2 | 2003 | 4 | 0.060 |
Why?
|
| Neuroblastoma | 2 | 2003 | 18 | 0.060 |
Why?
|
| Second Messenger Systems | 1 | 2006 | 6 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2003 | 126 | 0.060 |
Why?
|
| RNA Interference | 3 | 2014 | 36 | 0.060 |
Why?
|
| Response Elements | 1 | 2006 | 13 | 0.060 |
Why?
|
| Interleukin-1 | 1 | 2006 | 49 | 0.060 |
Why?
|
| Mice, Nude | 3 | 2013 | 25 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 1 | 2006 | 48 | 0.060 |
Why?
|
| Estradiol | 1 | 2006 | 51 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2004 | 324 | 0.060 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 200 | 0.060 |
Why?
|
| Transducin | 1 | 2004 | 1 | 0.050 |
Why?
|
| Guanosine Diphosphate | 1 | 2004 | 3 | 0.050 |
Why?
|
| Antimanic Agents | 1 | 2004 | 7 | 0.050 |
Why?
|
| Cell Line | 3 | 2011 | 254 | 0.050 |
Why?
|
| Glycine | 1 | 2003 | 7 | 0.050 |
Why?
|
| Chlorides | 1 | 2003 | 25 | 0.050 |
Why?
|
| Time Factors | 1 | 2006 | 1290 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2003 | 236 | 0.050 |
Why?
|
| Cobalt | 1 | 2003 | 106 | 0.050 |
Why?
|
| Neoplasm Transplantation | 2 | 2014 | 13 | 0.050 |
Why?
|
| Transgenes | 2 | 2014 | 10 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2021 | 3 | 0.040 |
Why?
|
| Pyridazines | 1 | 2021 | 2 | 0.040 |
Why?
|
| Models, Biological | 1 | 2003 | 306 | 0.040 |
Why?
|
| Piperidines | 1 | 2021 | 12 | 0.040 |
Why?
|
| Benzamides | 1 | 2021 | 13 | 0.040 |
Why?
|
| Exons | 1 | 2021 | 30 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2021 | 24 | 0.040 |
Why?
|
| Triazines | 1 | 2021 | 11 | 0.040 |
Why?
|
| Gene Knock-In Techniques | 2 | 2013 | 6 | 0.040 |
Why?
|
| Phenotype | 2 | 2014 | 258 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2020 | 21 | 0.040 |
Why?
|
| Hyaluronoglucosaminidase | 1 | 2020 | 2 | 0.040 |
Why?
|
| Drug Approval | 1 | 2020 | 5 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 18 | 0.040 |
Why?
|
| Imidazoles | 1 | 2021 | 62 | 0.040 |
Why?
|
| Gene Expression | 2 | 2012 | 180 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 40 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 82 | 0.040 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2012 | 26 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2020 | 6 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 153 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2020 | 9 | 0.040 |
Why?
|
| Hydrogen Peroxide | 1 | 2020 | 41 | 0.040 |
Why?
|
| CRISPR-Cas Systems | 1 | 2020 | 11 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 84 | 0.040 |
Why?
|
| Cell Survival | 1 | 2020 | 103 | 0.040 |
Why?
|
| NADPH Oxidases | 1 | 2020 | 44 | 0.040 |
Why?
|
| Cell Movement | 1 | 2020 | 78 | 0.040 |
Why?
|
| Biological Transport | 3 | 2004 | 38 | 0.040 |
Why?
|
| Adult | 3 | 2020 | 7078 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 251 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2020 | 339 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 102 | 0.040 |
Why?
|
| RAW 264.7 Cells | 1 | 2018 | 3 | 0.040 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 11 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 24 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2018 | 40 | 0.040 |
Why?
|
| Transplantation, Heterologous | 2 | 2009 | 20 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2018 | 20 | 0.040 |
Why?
|
| Pancreas | 1 | 2018 | 30 | 0.040 |
Why?
|
| Down-Regulation | 2 | 2009 | 90 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 359 | 0.030 |
Why?
|
| Pre-B-Cell Leukemia Transcription Factor 1 | 1 | 2017 | 1 | 0.030 |
Why?
|
| Alleles | 2 | 2007 | 163 | 0.030 |
Why?
|
| Aged | 2 | 2020 | 7562 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 521 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2017 | 285 | 0.030 |
Why?
|
| United States | 1 | 2020 | 1829 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2014 | 17 | 0.030 |
Why?
|
| Phospholipids | 2 | 2005 | 9 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2014 | 40 | 0.030 |
Why?
|
| Base Sequence | 1 | 2014 | 101 | 0.030 |
Why?
|
| Isotopes | 2 | 2005 | 2 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 188 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 61 | 0.030 |
Why?
|
| Binding, Competitive | 2 | 2004 | 22 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2013 | 2 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2013 | 6 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2013 | 2 | 0.030 |
Why?
|
| Point Mutation | 1 | 2013 | 25 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2013 | 42 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 3785 | 0.020 |
Why?
|
| Metribolone | 1 | 2012 | 1 | 0.020 |
Why?
|
| Tosyl Compounds | 1 | 2012 | 2 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2012 | 5 | 0.020 |
Why?
|
| Anilides | 1 | 2012 | 5 | 0.020 |
Why?
|
| Androgen Antagonists | 1 | 2012 | 4 | 0.020 |
Why?
|
| Androgens | 1 | 2012 | 7 | 0.020 |
Why?
|
| Nitriles | 1 | 2012 | 13 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2012 | 110 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2011 | 23 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2011 | 36 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2011 | 16 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 173 | 0.020 |
Why?
|
| Heterozygote | 1 | 2011 | 89 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 166 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2011 | 7 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2011 | 29 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2011 | 54 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 46 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2009 | 15 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2009 | 8 | 0.020 |
Why?
|
| Mammary Glands, Human | 1 | 2009 | 7 | 0.020 |
Why?
|
| Protein Kinases | 1 | 2009 | 11 | 0.020 |
Why?
|
| Biopsy | 1 | 2009 | 193 | 0.020 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2007 | 1 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2007 | 2 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2007 | 3 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2007 | 5 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 2007 | 5 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2007 | 31 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2007 | 10 | 0.020 |
Why?
|
| Telomerase | 1 | 2007 | 8 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2009 | 109 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2007 | 11 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2007 | 15 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2007 | 30 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2007 | 55 | 0.020 |
Why?
|
| Male | 3 | 2009 | 12655 | 0.020 |
Why?
|
| Dactinomycin | 1 | 2006 | 6 | 0.020 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2006 | 5 | 0.020 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2006 | 9 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 56 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 132 | 0.020 |
Why?
|
| Phosphorus Isotopes | 1 | 2005 | 1 | 0.010 |
Why?
|
| Binding Sites | 1 | 2005 | 69 | 0.010 |
Why?
|
| Protein Binding | 1 | 2005 | 115 | 0.010 |
Why?
|
| Rod Cell Outer Segment | 1 | 2004 | 1 | 0.010 |
Why?
|
| Guanosine Triphosphate | 1 | 2004 | 4 | 0.010 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2004 | 10 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2004 | 66 | 0.010 |
Why?
|
| Cattle | 1 | 2004 | 114 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2004 | 158 | 0.010 |
Why?
|
| Kinetics | 1 | 2004 | 179 | 0.010 |
Why?
|
| Sodium | 1 | 2003 | 56 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 2003 | 10 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2004 | 267 | 0.010 |
Why?
|
| Thermodynamics | 1 | 2003 | 42 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2003 | 54 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2003 | 130 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2003 | 481 | 0.010 |
Why?
|